Critical assessment of Belgian reimbursement dossiers of orphan drugs

PharmacoEconomics

Volumn 29, Issue 10, 2011, Pages 883-893

  Denis, Alain ^a   Mergaert, Lut ^a   Fostier, Christel ^a   Cleemput, Irina ^b   Hulstaert, Frank ^b   Simoens, Steven ^c  

^a Yellow Window Management Departments   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Decision making; Formularies; Health policy; Reimbursement

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANAGRELIDE; ANTIPARKINSON AGENT; ARSENIC TRIOXIDE; BOSENTAN; BUSULFAN; CARGLUMIC ACID; CO CARELDOPA; DASATINIB; DEFERASIROX; IDURONATE 2 SULFATASE; IMATINIB; LARONIDASE; LENALIDOMIDE; MIGLUSTAT; MITOTANE; NELARABINE; NITISINONE; ORPHAN DRUG; PEGVISOMANT; RAZOXANE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; SILDENAFIL; SITAXSENTAN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; ZINC ACETATE;

ACROMEGALY; ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ARTICLE; BELGIUM; BUDGET; CHELATION THERAPY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG COST; DRUG EXTRAVASATION; DRUG INDICATION; DRUG INDUSTRY; FABRY DISEASE; FUNDING; GASTROINTESTINAL TUMOR; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUNTER SYNDROME; HURLER SYNDROME; IRON OVERLOAD; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MULTIPLE MYELOMA; NAGS DEFICIENCY; ORGANIZATION; PARKINSON DISEASE; PERSONNEL MANAGEMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PULMONARY HYPERTENSION; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RISK REDUCTION; SAMPLE SIZE; THROMBOCYTOSIS; TYROSINEMIA; WILSON DISEASE;

BELGIUM; ECONOMICS, PHARMACEUTICAL; INSURANCE, HEALTH, REIMBURSEMENT; NATIONAL HEALTH PROGRAMS; ORPHAN DRUG PRODUCTION; RARE DISEASES; REIMBURSEMENT MECHANISMS;

EID: 80052784333     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11585980-000000000-00000     Document Type: Article

References (13)

1. European Commission. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official J European Communities 2000; L 18/1 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005: en:PDF [Accessed 2011 Jun 6]
2. European Commission. Register of designated orphan medicinal products. European Commission 2010 [online]. Available from URL: http://ec.europa.eu/ health/documents/community-register/html/orphreg.htm [Accessed 2010 Mar 19]
3. Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Policy 2010 Oct; 97 (2-3): 173-9
4. de Varax A, Letellier M, Börtlein G. Study on orphan drugs. Phase I: overview of the conditions for marketing orphan drugs in Europe. Paris: Alcimed, 2006 [online]. Available from URL: http://ec.europa.eu/health/files/ orphanmp/doc/pricestudy/final-final-report-part-1-web-en.pdf [Accessed2011 Jun 6]
5. Cleemput I, Van Wilder P, Vrijens F, et al. Guidelines for pharmaco-economic evaluation in Belgium. Brussels: Belgian Health Care Knowledge Centre, 2008 Report No. 78A
6. Royal Decree governing the procedures, terms and conditions for the reimbursement of the public insurance for health care and for pharmaceutical specialties [in Dutch and French]. Brussels: Belgisch Staatsblad, 2001 Dec 29
7. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical classification system for drugs. 2009 [online]. Available from URL: http://www. whocc.no/atc-ddd-index/ [Accessed 2011 Jun 6]
8. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. York: Centre for Reviews and Dissemination, 2001 Report No. 4
9. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001 Apr 14; 357 (9263): 1191-4 (Pubitemid 32378696)
10. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical trials in small populations. ondon: EMA, 2006 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003615pdf [Accessed 2011 Jun 6]
11. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health 2007 Sep-Oct; 10 (5): 336-47 (Pubitemid 47481105)
12. European Organisation for Rare Diseases. EURORDIS position paper on the Centralised procedure for the scientific assessment of the therapeutic added value of orphan drugs. Paris: EURORDIS, 2008 [online]. Available from URL: http://www.eurordis.org/IMG/pdf/position-paper-EURO RDIS-therapeutic-added- value-ODFeb08pdf [Accessed 2011 Jun 6]
13. The Pharmaceutical Forum. Improving access to orphan medicines for all affected EU citizens. 2008 [online]. Available from URL: http://ec.europa.eu/ pharmaforum/docs/pricing-orphans-en.pdf [Accessed 2011 Jun 6]